Septin-5 Antibody, Tissue Immunofluorescence Titer, Serum
Use
Septin-5 IgG is a biomarker of a rapidly progressive yet treatable form of autoimmune cerebellar ataxia. This condition manifests with a sudden onset of cerebellar ataxia and prominent symptoms related to eye movements, such as oscillopsia or vertigo. The condition may improve following immunotherapy. Detecting septin-5 IgG in serum specimens and reporting an end titer result assists in supporting the diagnosis of this autoimmune condition. If seropositivity is detected for septin antibodies through indirect immunofluorescence, it suggests an autoimmune disease of the central nervous system, warranting further confirmation via a cell-binding assay.
Special Instructions
Not provided.
Limitations
Negative results for septin antibodies do not exclude the possibility of neurological autoimmunity or cancer. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption. Results should be interpreted in conjunction with clinical findings and other diagnostic tests.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
Septin-5
Protein
LOINC Codes
- 101458-8 - Septin-5 IgG Titr SerPl IF
- 101458-8 - Septin-5 IgG Titr SerPl IF
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
Not provided
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial. Preferred collection container is red top, but serum gel is acceptable.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |